相关实验视频

Updated: May 2, 2026

Rapid Identification of Chemical Genetic Interactions in Saccharomyces cerevisiae

Rapid Identification of Chemical Genetic Interactions in Saccharomyces cerevisiae

Published on: April 5, 2015

用抗癌药物5-Fluorouracil针对人体pyruvate kinase m2的分子对接和分子动态模拟研究进行光谱洞察

Mamali Priyadarshinee¹, Budheswar Dehury², Sarbani Mishra²

¹Department of Life Sciences, Ravenshaw University, Cuttack, India.

Journal of biomolecular structure & dynamics

|February 12, 2024

概括

这项研究表明,5-fluorouracil (5-FU) 有效地与人体的pyruvate kinase异酶M2 (PKM2) 结合,破坏其结构的稳定,并可能抑制其作为抗癌机制的生物活性.

科学领域:

生物化学生物化学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

酸盐酶单酶M2 (PKM2) 是癌症代谢中的一个关键酶.
准PKM2是抗癌药物开发的一个有前途的战略.
5-甲 (5-FU) 是一种广泛使用的化疗剂.

研究的目的:

通过检查其与人类酸激酶M2 (PKM2) 的相互作用来研究5-fluorouracil (5-FU) 作为抗癌剂的疗效.
阐明PKM2.2上由5-FU诱导的结合机制和构造变化.

主要方法:

使用光谱技术 (光火,圆形二重化) 来研究PKM2-5-FU相互作用.
进行了分子对接和全原子分子动态模拟,以分析结合模式和稳定性.
计算了热力学参数 (,,自由能量) 来描述结合过程.

主要成果:

5-FU表现出一种自发且稳定的与PKM2的结合,主要是通过静电和结合相互作用.
5-FU的结合导致α-螺旋的含量下降和PKM2的轻微形状变化,表明不稳定.
光谱和模拟研究始终支持稳定的5-FU-PKM2复合物的形成.

结论:

5-甲 (5-FU) 有效地结合并损害了pyruvate kinase异酶M2 (PKM2) 的生物活性.
相互作用涉及静电和键,导致PKM2.2的结构不稳定.
这项研究为通过PKM2抑制的5-FU抗癌功效提供了机制基础.

关键词:

5 - - 甲酸是一种甲.在PKM2中,PKM2是PKM2.乳腺癌乳腺癌乳腺癌分子对接的分子对接.分子动态模拟分子动态模拟光谱学的洞察力

更多相关视频

Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides

Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides

Published on: July 26, 2018

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...